eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | metabolic syndrome x |
| Symptom | C0020538|hypertension |
| Sentences | 113 |
| PubMedID- 22422828 | hypertension as part of the metabolic syndrome has been frequently related to end-stage renal disease. |
| PubMedID- 24678944 | Sympathoexcitation and oxidative stress in the brain have pivotal roles in hypertension with metabolic syndrome (mets). |
| PubMedID- 20405160 | Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in germany, spain and italy. |
| PubMedID- 26064845 | In fact, insulin resistance, dyslipidemia, obesity and hypertension, each of these variables of metabolic syndrome gets influenced by the serum uric acid level. |
| PubMedID- 24729809 | All parameters of metabolic syndrome with resolving/improving t2dm, hypertension, joint disease, depressive disorders or sleep apnoea are normalized or markedly improved after lsg. |
| PubMedID- 21286276 | Abnormalities of sodium transport regulation have also been implicated in the pathogenesis of hypertension associated with the metabolic syndrome. |
| PubMedID- 20798846 | In large cohorts, ghrelin is higher in women than men and declines with age, body mass index (bmi), hypertension, and other markers of the metabolic syndrome . |
| PubMedID- 22963383 | Obesity and metabolic syndrome combined with hypertension in shr-ob but not hypertension alone in shr-lean resulted in a moderate decrease in lv-systolic function when compared to normotensive controls but lv-systolic global contractility was preserved as indicated by lv-pressure measurements. |
| PubMedID- 24209601 | In multivariable analysis, female gender, age > 65 years, smoke, non-hypertension, duration of diabetes > 10 years, metabolic syndrome, egfr < 90 ml/min/1.73 m2, and ga > 18.3% were independently determinants for low collateralization in diabetic patients. |
| PubMedID- 22808030 | Furthermore, microparticles promote endothelial dysfunction in metabolic syndrome patients with moderate hypertension 8. |
| PubMedID- 23727924 | Obesity is closely related to several chronic diseases such as diabetes, cardiovascular diseases, hyperlipidemia or hypertension that are associated with metabolic syndrome. |
| PubMedID- 20368993 | Our findings now suggest that seasonal weight gain bridges npas2 and hypertension to the pathogenesis of the metabolic syndrome. |
| PubMedID- 20718958 | In drug treatments of hypertension associated with metabolic syndrome, the mechanisms which generate hypertension such as the increase in activity of the renin-angiotensin system and sympathetic system as well as the increase of sodium absorption, should be interfered with if possible always with the aim of decreasing cardiovascular morbi-mortality. |
| PubMedID- 23573411 | hypertension in metabolic syndrome: vascular pathophysiology. |
| PubMedID- 22190906 | Vascular endothelial dysfunction has been demonstrated in metabolic syndrome with and without hypertension or diabetes . |
| PubMedID- 25306760 | Arterial hypertension in metabolic syndrome: pathophysiological aspects. |
| PubMedID- 20813031 | The prevalence of hypertension with metabolic syndrome in the general population of germany, spain and italy was 36%, 11% and 10% respectively. |
| PubMedID- 24798707 | metabolic syndrome induces hypertension and commonly results in renal damage. |
| PubMedID- 20016031 | Although recent evidence underscores the role of heme-oxygenase (ho) in diabetes, its effects on insulin sensitivity and glucose metabolism in spontaneously hypertensive rat (shr), a model of essential hypertension with characteristics of metabolic syndrome including insulin resistance/impaired glucose metabolism remains largely unclear. |
| PubMedID- 23524523 | Objective: obesity, diabetes, fatty liver, and hypertension are major determinants of the metabolic syndrome. |
| PubMedID- 23318820 | Introduction: the treatment of arterial hypertension (ah) in patients with metabolic syndrome (ms) is a challenge, since non drug therapies are difficult to implement and optimal pharmacological treatment is not fully established. |
| PubMedID- 22829804 | hypertension is another component of the metabolic syndrome which is independently associated with increased cardiovascular risk. |
| PubMedID- 22691241 | Logistic regression (backward selection) was further performed to calculate odds ratios (ors) for high versus low homa-ir according to demographic and lifestyle (gender, age, tobacco use), metabolic (obesity, hypertension, use of statins, metabolic syndrome), and clinical parameters, including the das28, health assessment questionnaire (haq), crp, and ra treatment modality (glucocorticoids, methotrexate). |
| PubMedID- 25916862 | Renin-angiotensin-aldosterone system (raas) inhibition with an ace or an arb and treatment with calcium channel blockers appears safe and well tolerated in obesity-related hypertension and in patients with metabolic syndrome. |
| PubMedID- 22131755 | furthermore, insulin-resistant patients, with and without type 2 diabetes, are at an increased risk for developing metabolic syndrome, a major cause of heart disease, hypertension and dyslipidemia. |
| PubMedID- 23837919 | hypertension clusters with metabolic syndrome, diabetes, and hepatic steatosis, and requires life-long pharmacologic treatment. |
| PubMedID- 23517220 | Abpm should be a priority for persons likely to have a blunted nighttime bp decline and elevated cvd risk, i.e., those who are elderly and obese, those with secondary or resistant hypertension, and those diagnosed with diabetes, ckd, metabolic syndrome, and sleep disorders. |
| PubMedID- 23931752 | The role of the sympathetic nervous system, stress, and hypertension in metabolic syndrome and obesity remains unclear. |
| PubMedID- 24658007 | Hsd11b1 enzymatic activities are thought to be involved in obesity, hypertension, and other components of the metabolic syndrome. |
| PubMedID- 21107432 | The prevalence of metabolic syndrome (mets) in patients with essential hypertension is very high, and has been estimated as being close to 50%.1 hypertensive patients with mets have a much higher cardiovascular (cv) risk than their counterparts without mets,2 and also have a particularly high risk of developing type 2 diabetes mellitus (t2dm).3 in addition, the choice of antihypertensive therapy can have a large impact on the risk of development of t2dm.4 renin–angiotensin system blockers, that is, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (arbs), improve insulin sensitivity and reduce the risk of developing t2dm compared with placebo, whereas calcium channel blockers (ccbs) have a neutral effect. |
| PubMedID- 22261288 | Although more studies are needed to determine whether these short-term increases or the longer-term decreases in adiposity modify the risk on chronic diseases such as diabetes mellitus, hypertension or other components of the metabolic syndrome, the widely held concern that preterm babies have greater adiposity than their term peers, and that this is worsened by greater amounts of catch-up growth, are not supported by the available evidence. |
| PubMedID- 21623724 | Possibilities of the use of moxonidine in the treatment of arterial hypertension in patients with metabolic syndrome and diabetes. |
| PubMedID- 20213371 | In addition, in refractory hypertension and in patients with metabolic syndrome aldosterone seems to play an important role. |
| PubMedID- 23205504 | Exercise-induced hypertension in men with metabolic syndrome: anthropometric, metabolic, and hemodynamic features. |
| PubMedID- 25464609 | Material and methods: we conducted an 8-week open prospective study on 36 patients with essential stage ii hypertension associated with metabolic syndrome. |
| PubMedID- 22866890 | The hfcd-fed sd rats developed a severe metabolic syndrome consistent with hypertension and hypercholesterolemia. |
| PubMedID- 22293193 | Salt-sensitive hypertension is a characteristic of the metabolic syndrome. |
| PubMedID- 23835856 | Conclusions: in this study, children's hypertension was a component of the metabolic syndrome, but uric acid and hscrp levels were not contributive. |
| PubMedID- 24474950 | Sixty-six self-identified african-american subjects with stage 1 and 2 hypertension and characteristics of the cardiometabolic syndrome were treated with amlodipine/olmesartan (a/o) versus losartan/hydrochlorothiazide (l/h) for 20 weeks in an open-label, active comparator fashion. |
| PubMedID- 23024568 | The comorbid relationship between stroke and migraine may relate to observations that migraineurs have increased adiposity, reduced insulin sensitivity, an unfavourable lipid profile and hypertension, all features of the metabolic syndrome, a known risk factor for cerebrovascular disease. |
| PubMedID- 21471972 | There is evidence that uncontrolled arterial hypertension (aht) in patients with metabolic syndrome (ms) increases cardiovascular risks. |
| PubMedID- 21155616 | Background and objective: metabolic syndrome is common in patients with hypertension and increases the risk of developing diabetes mellitus. |
| PubMedID- 21143427 | Dietary fructose, salt absorption and hypertension in metabolic syndrome: towards a new paradigm. |
| PubMedID- 24467657 | These results suggest that increases in atp content in rvlm is engaged in the augmented sympathetic vasomotor activity and hypertension associated with metabolic syndrome induced by the hfd. |
| PubMedID- 25906108 | hypertension, a component of the metabolic syndrome, was indicated to be associated with prostate cancer.17,43,44 however, not all epidemiological studies have supported this link.12,13 in this study, more prostate patients were observed in the hypertension group, but the difference did not reach the statistically significant level (adjusted hr = 1.20, 95% ci = 0.97–1.47). |
| PubMedID- 22473401 | metabolic syndrome was significantly associated with hypertension, insulin resistance, increased abdominal fat, and overweight. |
| PubMedID- 24485020 | Insulin resistance and hypertension are the components of metabolic syndrome and often coexist 4. |
| PubMedID- 25364674 | As a consequence, they are at high risk for dm, hypertension, and other features of metabolic syndrome. |
| PubMedID- 20383279 | Whereas arbs and acei have demonstrated their efficiency in improving insulin sensitivity and reducing end-organ damage and are now often considered as first-line therapy in hypertension with metabolic syndrome or diabetes , , association of anti-oxidants or anti-nitrants in an attempt to further reduce deleterious nitrative stress might be worth considering in severely affected or non-responsive patients. |
| PubMedID- 21659755 | There is considerable evidence that obesity, hypertension and other elements of the metabolic syndrome also contribute to the progression of renal disease independent of diabetes. |